Please assess the completion status of the following clinical trial:

Trial Title: Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified intra- or extrahepatic inoperable hepatocellular carcinoma or hyperdense liver lesion at computed tomography and concurrent elevated alpha-feto-protein \> 400 ng/ml~* PS 0-2~* Age 18-75~* Life expectancy \> 12 weeks~* Normal bone marrow function (neutrophiles \> 1,5 x 109/l and platelets \> 100 x 109/l)~* Bilirubin \< 2 x UNL~* Transaminases \< 3 x UNL~* Normal renal function, Cr-EDTA clearance \> 50 ml/min~* No chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion~* No uncontrolled, severe concurrent medical disease~* Fertile women must have a negative pregnancy test~* Fertile women must use adequate contraceptives during and 3 months after trial exposure~* Signed informed consent~Exclusion Criteria:~* Chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion~* Experimental therapy \< 8 weeks prior to inclusion~* Known DPD-deficiency~* Known neuropathy~* Uncontrolled, severe concurrent medical disease~* Prior malignancy during the last 5 years, except for non-melanoma skin cancer and carcinoma in situ cervix uteri.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).